期刊文献+

中枢神经系统白血病患者脑脊液中MMP-2和TNF-α水平变化及意义 被引量:1

Level change of MMP-2 and TNF-α in cerebrospinal fluid of patients with central nervous system leukemia,and its significance
下载PDF
导出
摘要 目的探讨中枢神经系统白血病(CNSL)患者脑脊液(CSF)中基质金属蛋白酶-2(MMP-2)和肿瘤坏死因子-α(TNF-α)水平及意义。方法采用酶联免疫吸附试验检测31例CNSL患者(CNSL组)、42例非CNSL患者(非CNSL组)、30例非中枢神经系统疾病和肿瘤的患者(对照组)CSF中MMP-2、TNF-α的水平,并进行比较分析。结果 CNSL组和非CNSL组患者CSF中MMP-2、TNF-α水平均高于对照组,CNSL组患者CSF中MMP-2、TNF-α水平均高于非CNSL组(P<0.05)。结论 CNSL患者CSF中MMP-2、TNF-α明显高表达,两者可能参与了CNSL的发生发展,检测CSF中MMP-2、TNF-α水平有助于CNSL的早期诊断。 Objective To investigate the level change of matrix metalloproteinases-2 (MMP-2) and tumor necrosis factor-α (TNF-α) in cerebrospinal fluid (CSF) of patients with central nervous system leukemia (CNSL) and their significances. Methods Enzyme linked immunosorbent assay was used to detect the levels of MMP-2 and TNF-αof CSF in the 31 patients with CNSL (the CNSL group), the 42 patients with non-CNSL leukemia (the non-CNSL group), the 30 patients without central nervous system diseases and neoplasms (as the control group), and the levels of MMP-2 and TNF-α in above groups were analyzed comparatively. Results The levels of MMP-2 and TNF-α of CSF in the CNSL group and the non-CNSL group were higher than those of the control group, the levels of MMP-2 and TNF-α of CSF in the CNSL group were higher than those of the non-CNSL group (P&lt;0.05). Conclusion The high expressions of MMP-2 and TNF-α of CSF are observed in the patients with CNSL, MMP-2 and TNF-α may be involved in the occurrence and development of CNSL,thus detecting the MMP-2 and TNF-α of CSF can be used to early diagnose the CNSL.
机构地区 解放军
出处 《实用医药杂志》 2014年第7期587-588,共2页 Practical Journal of Medicine & Pharmacy
关键词 白血病 中枢神经系统 脑脊液 基质金属蛋白酶-2 肿瘤坏死因子-α Leukemia Central nervous system Cerebrospinal fluid Matrix metalloproteinase -2 Tumor necrosis factor-α
  • 相关文献

参考文献10

二级参考文献74

共引文献56

同被引文献8

  • 1Vandraas KF, Vikanes V, St#er NC, et al. Hyperemesis gravida- rum and risk of cancer in offspring, a Scandinavian registry - based nested case - control study [ J ]. BMC Cancer, 2015 ( 15 ) : 398.
  • 2Yaron A, Bradley HS. suPAR: A Cardiac Biomarker With a Fu- ture? [J]. Can J Cardiol, 2015, 31(10) : 1223 -1226.
  • 3Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasma. In : WHO Classification of Turnouts of I-Iaematopoietic and Lymphoid Tissue Tumor[M]. 4th ed. France Lyon . International Agency for Re- search on Cancer, 2008:167 -178.
  • 4Naomi JW. The evolution of central nervous system prophylaxis for patients with acute lymphoblastic leukemia [ J ]. Pediatr Blood Cancer, 2015, 62(11) : 1877 -1884.
  • 5Erknt N. The Prognostic Significance of soluble urokinase plasmino- gen activator receptor in acute myeloid leukemia [ J ]. Turk J Haematol, 2015, 32(2) : 1012 - 1016.
  • 6Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the Uroki- nase type plasminogen activator receptor by metaloproteinase - 12: implication for angiogenesis in fibrin matrices[J]. Blood, 2001,97 (10) : 3123 -3131.
  • 7孙艳花,陈子兴,江森,岑建农,姚利.急性白血病患者脑脊液中可溶性CD44的测定及其在中枢神经系统白血病诊断中的意义[J].中华血液学杂志,2011,32(1):57-58. 被引量:5
  • 8吕晓东,韩利杰,辛雅萍,王献伟,宋云峰.脑脊液中WT1基因检测在中枢神经系统白血病检测中的意义[J].中国实用神经疾病杂志,2014,17(18):56-57. 被引量:4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部